How much does a stem cell transplant for multiple myeloma cost?
STCs can be expensive, and may cost between $140,792 and $289,283 . Medicare covers part of the costs of two types of FDA-approved stem cell therapy, or transplants.
How many times can you have a stem cell transplant for multiple myeloma?
Some doctors recommend that patients with multiple myeloma have 2 autologous transplants, 6 to 12 months apart. This approach is called tandem transplant. Studies show that this may help some patients more than a single transplant. The drawback is that it causes more side effects and as a result can be riskier.
Is stem cell transplant painful?
The transplant The stem cells will be passed slowly into your body through the central line. This process often takes around a couple of hours. The transplant won’t be painful and you’ll be awake throughout.
Is it possible to get a stem cell transplant for multiple myeloma?
An autologous stem cell transplant is more common for treating multiple myeloma. How effective is stem cell transplantation? In the treatment of multiple myeloma, stem cell transplants have been shown to lengthen patients’ remission period.
Do you need a donor for autologous stem cell transplant?
With an autologous transplant, the healthy stem cells are taken from the patient’s own body. On the other hand, an allogeneic transplant requires a donor. An autologous stem cell transplant is more common for treating multiple myeloma. How effective is stem cell transplantation?
What is the standard of care for multiple myeloma?
The standard of care for fit multiple myeloma patients is to receive high-dose chemotherapy (HDT) with autologous stem cell rescue — otherwise known as autologous stem cell transplant (ASCT) — after completion of induction therapy.
Which is better inpatient or outpatient autologous stem cell transplantation?
Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma Outpatient auto-HCT can be safely performed for selected patients with MM. Differences in outcomes are likely related to baseline clinical characteristics rather than choice of treatment setting.